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B E D A C
HNSCC Head and neck squamous cell carcinoma 
ATCC American type culture collection 
BrdU 5-Bromo-2-Deoxyuridine 
BSA Bovine Serum Albumin 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl Sulfoxide 
DXM Dexamethasone 
EB Ethidium Bromide 
ECM Extracellular Matrix 
FCS Fetal Calf Serum 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
HCl Hydrogen Chloride 
M Mole 
mM Millimole 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium 
nM Nanomole 
µM micromole 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
P/S Penicillin/ treptomycin 
PH Hydrogen Ion Concentration 
SKY Spectral karyotyping hybridization 
STR Short tandem repeat 
SHH Sonic Hedgehog 
TNM TNM Classification of Malignant Tumors 
U Unit 
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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is one of the six malignant lesions 
worldwide with the highest incidence rate, and accounts for 90% of all oral cancers (Jemal et 
al., 2011). Current curative treatment approaches include surgery, irradiation and irradiation 
in combination with chemo- or immunotherapy, depending on the stage of the lesion. Due to 
the low 5-year survival rate and the high recurrence rate of HNSCC, new chemotherapeutic 
strategies are of high clinical interest. The discovery and development of effective 
chemotherapeutic agents for HNSCC is essential. Despite tremendous research efforts, the 
prognosis for affected patients remains dismal, particularly for those with locally advanced 
disease. Additionally, the impact on their quality of life is substantial (de Bree et al., 2000). 
Several factors may contribute to these disappointing results, including acquired drug 
resistance and tumor hypoxia (Denaro et al., 2012). 
1.1 Integrin pathway 
Integrins are heterodimeric transmembrane glycoproteins composed of two subunits α and β, 
together forming more than 24 different proteins using 18 α and 8 β subunits. They have a 
crucial role in cell-cell adhesion and cell interaction with the extracellular matrix (ECM). 
Integrins bind with specific ECM proteins, such as fibronectin, laminin, collagen, vitronectin 
and fibrinogen, through specific ligands that recognize the Arg-Gly-Asp (RGD) tripeptide 
motif (Seguin et al., 2015). The α subunit, consisting of about 1100 amino acids, is the largest 
subunit and is composed of chains of different length held together by two disulfide bridges. 
The β subunit consists of about 800 amino acids, with the exception of the β4 subunit, which 
contains about 1750 amino acids. Both the α and β subunits have a small transmembrane 
region, a large extracellular domain and a small cytoplasmic tail. The cytoplasmic domain is 
crucial for the regulation of integrin activity. It controls the integrin affinity state and its ECM 
ligand-binding activity, and promotes cellular responses upon extracellular ligand binding. 
After activation of the cytoplasmic domain by its extracellular ligand, integrins, which lack 
intrinsic kinase activity, cluster to form cell membrane focal adhesion complexes. Focal 
adhesion kinase (FAK) is recruited and autophosphorylated at these sites, in turn activating 
signaling pathways through phosphatidylinositol 3-kinase (PI3K), nuclear factor kappa B 
(NF-kB), sarcoma tyrosine kinase (SRC) and extracellular signal-regulated kinase 
(ERK/MAPK) (Fig. 1) (Reardon and Cheresh, 2011).  
 
Figure 1: Schematic representation of main signaling pathways activated by integrins(Reardon and 
Cheresh, 2011).  
 
This leads to the regulation of several cellular processes, including cell motility and invasion, 
remodeling of the ECM by means of localization proteases, cell growth through adhesion-
dependent control of proliferation, and cell signaling by cross-talk with growth factors and 
cytokine receptors. In addition, integrins are involved in several steps of normal immune-cell 
function, including T-cell activation and lymphocyte adhesion to endothelial cells (Reardon 
and Cheresh, 2011), and modulate apoptosis, regulating the activity of pro-apoptotic proteins, 
such as caspase, through a mechanism called integrin-mediated death (Buckley et al., 1999). 
However, the exact molecular mechanisms and pathways involved in their actions remain 
unclear.  
Cilengitide is a cyclized Arg-Gly-Glu (RGD)-containing pentapeptide that selectively blocks 
activation of the αvβ3 and αvβ5 integrins (Goodman et al., 2002). Cilengitide has been used 
for inhibiting rapid growth of highly vascularized tumors, highlighting the potential of this 
new therapeutic agent (Raguse et al., 2004). It may have a direct effect on the migration, 
attachment and viability of tumor cells. Studies of cilengitide have focused mainly on 
glioblastoma (MacDonald et al., 2008). No data have been published on the effect of 
cilengitide on primary HNSCC cell cultures.  
In previous studies, most cell lines were purchased from commercial companies (Liu et al., 
2016, Sasahira et al., 2016). These cell lines may have already differentiated and lost some of 
their potential characteristics as tumor cells. In contrast, primary cell cultures may retain their 
internal biological characteristics (Manikandan et al., 2016). Accordingly, we isolated and 
identified primary HNSCC cell cultures, and evaluated the effects of cilengitide on those 
cultures and on cell lines. The application of drugs to the cell lines or primary cell cultures 
may produce different results. 
1.2 Hedgehog signal pathway 
Recently, growing evidence has suggested that aberrant activation of the Hedgehog signaling 
(HH) pathway in squamous cell carcinoma (SCC) plays a critical role during cancer 
development (Yan et al., 2011, Liebig et al., 2017). Canonical HH signaling is initiated by the 
binding of HH ligands (Sonic, Indian and Desert hedgehog) to a 12-transmembrane receptor 
Patched (PTCH), which relieves the catalytic inhibition of Smoothened (SMO), a 7-
transmembrane G-protein coupled receptor (GPCR)-like signal transducer. SMO de-
repression triggers a series of intracellular events, resulting in the activation of downstream 
target genes through the zinc finger transcription factors GLI1, GLI2 and GLI3 (Lum and 
Beachy, 2004). GLI activation is complex with regulation at both the transcriptional and post-
translational levels (Ruiz i Altaba et al., 2007). GLI2 appears to be the primary activator of 
HH signaling in cancer, with GLI1 as a transcriptional target of GLI2 (Bai et al., 2002, Ikram 
et al., 2004). GLI2 and GLI1 also induce transcription of overlapping and distinct sets of 
downstream targets (Eichberger et al., 2006). Several components of the HH pathway (PTCH, 
GLI1, GLI2, HHIP) are GLI transcriptional targets that induce positive or negative feedback 
(Bigelow et al., 2004). GLI targets mediate various cellular responses, notably enhanced cell 
proliferation and survival, by upregulating D-type cyclins and anti-apoptotic proteins 
(Bigelow et al., 2004). Finally, phosphatidylinositol 3-kinase (PI3K)/AKT and RAS-MEK 
signals have been described as non-canonical HH activators in cancer (Nolan-Stevaux et al., 
2009, Riobo et al., 2006). Upon HH binding, PTCH1 translocates out of the primary cilium, 
losing its ability to inhibit SMO, which moves into the cilium, thus stimulating the pathway 
and preventing GLI2 and GLI3 cleavage. Activated GLI2 and to a lesser extent GLI3 then 
bind to GLI-promoters in the nucleus and stimulate transcription of the ubiquitous 
mammalian target genes, GLI1, PTCH1, and HHIP, and also cell-type specific genes, which 
can include BCL2, Cyclins and Snail. PTCH1 and HH are internalized and degraded in 
lysosomes (Fig. 2).  
 Fig. 2: The basic components of the mammalian Hedgehog signaling pathway. (a) In the 
absence of HH ligands. (b) With HH ligands. Shown in red are various Hedgehog signaling 
pathway antagonists (Scales and de Sauvage, 2009). 
 
Dysregulation of the HH pathway has been implicated in a variety of cancers (Scales and de 
Sauvage, 2009). Although the involvement of HH signaling in SCC is well established (Yan 
et al., 2011, Liebig et al., 2017), the role of this pathway remains poorly understood. 
However, multiple lines of evidence point to the potential importance of HH signaling in 
SCC. Immunohistochemical studies of patient specimens reported the overexpression of HH 
signaling components (Cavicchioli Buim et al., 2011, Dimitrova et al., 2013, Srinath et al., 
2016, Kuroda et al., 2017). HH signaling has also been implicated in squamous cancer of 
other organs (Szkandera et al., 2013, Huang et al., 2014). Despite these studies, very little is 
known regarding the specific role of HH signaling in regulating cellular survival and 
proliferation in HNSCC. Targeted inhibitors of the HH pathway have become available 
recently. Because of its accessibility on the membrane and its importance in regulation of the 
pathway, SMO has been the primary focus in the development of small molecule inhibitors of 
the HH pathway. Vismodegib (GDC-0449) is an orally administered agent that selectively 
suppresses SMO activity, and was the first SMO inhibitor to progress to clinical trials. It has 
produced promising antitumor responses in patients with advanced basal cell carcinoma and 
medulloblastoma (Rudin et al., 2009, Von Hoff et al., 2009), but resistance has been reported 
(Dijkgraaf et al., 2011, Yauch et al., 2009). The resistance to SMO inhibitors highlights the 
therapeutic need to target downstream effectors to maintain robust on-target responses. To our 
knowledge, there is still a lack of data from clinical trials regarding the effect of vismodegib 
on HNSCC. 
1.3	The	hypothesis	of	this	study	 	
Due to the low 5-year survival rate and the high recurrence rate of HNSCC, new 
chemotherapeutic strategies are of high clinical interest. Integrins are important adhesion 
molecules and play a regulatory role in many critical biological processes such as cell 
proliferation, invasion, apoptosis, metastasis, and angiogenesis in squamous cell carcinoma. 
Cilengitide is a cyclized RGD containing pentapeptide that selectively blocks activation of the 
integrins. Studies of cilengitide have focused mainly on glioblastoma (MacDonald et al., 
2008). No data have been published on the effect of cilengitide on primary HNSCC cell 
cultures. 
Recently, growing evidence has suggested aberrant activation of the hedgehog signal pathway 
in squamous cell carcinoma plays a critical role during cancer development. Vismodegib 
(GDC-0449) is an orally administered agent that selectively suppresses SMO activity of the 
HH pathway. HH signal pathway has also been implicated in squamous cancer of other organs 
(Szkandera et al., 2013, Huang et al., 2014). Despite of these studies, very little is known 
regarding the specific role of HH signaling in regulating cellular survival and proliferation in 
HNSCC. 
Most previous studies used cell lines purchased from commercial companies. These cell lines 
may already have differentiated and lost some of their potential characteristics as tumor cells. 
Therefore, the aim of the whole research study was to 
1. Isolate and identify primary HNSCC cell cultures 
2. Evaluate the effects of cilengitide and vismodegib on the proliferation of cells 
3. Demonstrate the change of gene expression after application of drugs to the cell lines or 
primary cell cultures respectively. 
 
  
2. Material and methods 
2.1 Materials 
Material Catalog number Manufacturer
Tissue culture plate 96-well 83.1835.300 SARSTEDT, Numbrecht 
Tissue culture plate 6-well 83.1839.300  SARSTEDT, Numbrecht
Falcon Tube 15 ml 62.553.042 SARSTEDT, Numbrecht
Falcon Tube 50 ml 62.547.254 SARSTEDT, Numbrecht
Flask T75                                83.3911.002 SARSTEDT, Numbrecht
Serological Pipette 25 ml                    86.1685.001 SARSTEDT, Numbrecht
Serological Pipette 10 ml                   86.1254.001 SARSTEDT, Numbrecht
Serological Pipette 1 ml                     86.1251.001 SARSTEDT, Numbrecht 
Biosphere Filter Tips 0.5-10 µl                                 70.115.210 SARSTEDT, Numbrecht 
Biosphere Filter Tips 2-100 µl                                 70.760.212 SARSTEDT, Numbrecht 
Biosphere Filter Tips 100-1000 
µl 
70.762.211 SARSTEDT, Numbrecht 
Combitips advanced 1 ml               0030089545 EppendorfBiopur, Hamburg 
Combitips advanced 5 ml             0030089669   EppendorfBiopur, Hamburg 
CryoRure Tube 1.8 ml Nunc 
Lab-Tek II 
72.379 SARSTEDT, Numbrecht 
Chamber Slide 154534 Thermo Scientific, Rochester, 
USA 
  
2.2	Reagents	 	
Reagent Catalog number Manufacturer
Primer SHH                            QT01156799 QIAGEN, Hilden, Germany
Primer GLI1                           QT00060501  QIAGEN, Hilden, Germany
Primer SUFU                       QT00050260     QIAGEN, Hilden, Germany
Primer SMO                           QT00050701  QIAGEN, Hilden, Germany
Primer PTCH                        QT00075824    QIAGEN, Hilden, Germany
Primer ITGAV                     QT00051891 QIAGEN, Hilden, Germany
Primer ITGB3                   QT00044590   QIAGEN, Hilden, Germany
Primer ITGB5                      QT00044520 QIAGEN, Hilden, Germany 
Primer GAPDH                  QT00079247    QIAGEN, Hilden, Germany 
Cell Proliferation kit I (MTT)    11645007001 Roche Applied Science, 
Indianapolis, USA 
 
Cell Proliferation ELISA kit 
(BrdU)     
11647229001 Roche Applied Science, 
Indianapolis, USA 
 
DNA Ladder 25-700 bp                    SM1191 Thermo Scientific, NY, USA 
Dulbecco’s MEM (DMEM)         T041-01              Biochrom AG, Berlin, 
Germany 
Ethidium Bromide              1.11608.0010   Merck K GaA, Germany 
FCS                                   S0115 Biochrom AG, Berlin, 
Germany 
Anti-CD90 / Thy1 antibody            ab133350 ABcam, San Francisco, CA, 
USA 
Anti- Cytokeratin antibody              ab7753 ABcam, San Francisco, CA, 
USA 
Anti-SHH antibody                    ab53281 ABcam, San Francisco, CA, 
USA 
Anti-Vimentin antibody                ab20346 ABcam, San Francisco, CA, 
USA 
PBS powder  
without Ca2+, Mg2+                   
L182-10 Biochrom AG, Berlin, 
Germany 
Biotin Blocking System                   X0590 Dako, Copenhagen, Denmark 
LSAB+ System-HRP                     K0679 Dako,Copenhagen, Denmark 
Molecular Biology Agarose        161-3102       Bio-Rad Laboratories, CA, 
USA 
Penicillin/ Streptomycin                  A2213 Biochrom AG, Berlin, 
Germany 
Propidium Iodide P4710 Sigma-Aldrich Chemistry 
GmbH, Steinheim, Germany 
QuantiTect SYBR Green RT-
PCR kit   
204243 Qiagen, Hilden, Germany 
Rneasy plus Mini kit                        74134 Qiagen, Hilden, Germany 
QuantiTect reverse 
transcription kit              
205311 Qiagen, Hilden, Germany 
Cilengitide                          S707702 Selleck chemicals, Houston, 
USA 
Vismodegib S603832 Selleck chemicals, Houston, 
USA 
KaryoMAX® Colcemid™ 
Solution 
15210-040 GIBCO, CA, USA 
  
 
2.3 Instruments 
Instrument Manufacturer
8-channel Piette with adjustable volume Eppendorf AG, Hamburg, Germany
BioDocAnalyze System Biometra, Goettingen, Germany
BLAUBRAND-Hemoctyometer Brand GmbH CO. KG, Wertheim, 
Germany
Centrifuge 5702R Eppendorf AG, Hamburg, Germany
Coolpix MDC lens Nikon Corporation, Tokyo, Japan
Einfrierbox (cry®box)   Nunc A/S, Roskilde, Denmark
Eppendorf single-channel pipette 1 - 10 
µl   
Eppendorf AG, Hamburg, Germany 
Eppendorf single-channel pipette 10 - 
100 µl 
Eppendorf AG, Hamburg, Germany 
Eppendorf single-channel pipette 100 – 
1000 µl 
Eppendorf AG, Hamburg, Germany 
 
Emitech K-850 Critical Point Drier Emitech Products Inc,Butte Creek, Texas, 
USA 
Filtration device SM 16510   Sartorius GmbH, Germany 
GX-600 A&D Company, Ltd, Japan 
Heraeus HERA-cell 240 CO2-Incubator Kendro Laboratory Products GmbH, 
Hanau, Germany
Invert-Microscope Leitz GmbH, Wetzlar, Germany 
Light Cycler® 2.0 Roche, Mannheim, Germany 
Microscope M 420 Wild Heerbrugg, Switzerland 
Microphoto-FXA Nikon Corporation, Tokyo, Japan 
Mini Gel Migration Trough Cosmo Bio Co. Ltd, Germany 
Nikon Coolpix 5000    Nikon Corporation, Tokyo, Japan 
SOFTmax Pro   Molecular Devices, Sunnyvale, CA, USA 
SPECTRA MAX Plus   Olecular Devices, Sunnyvale, CA, USA 
Vortexer: Vortex Genie 2   Bender&Hobein, Schweiz, Germany 
2.4 experimental scheme  
 
 
Fig. 3: Experimental scheme of the whole research study.  
  
  
2.5 Isolation and culture of SCCs 
2.5.1 Cell lines 
Four tongue squamous cell carcinoma cell lines (SCC4, SCC9, SCC15 and SCC25) were 
obtained from the American Type Culture Collection. The cells were cultured in DMEM 
medium containing 10% fetal bovine serum in an incubator with 5% CO2 at 37 °C. The 
medium was refreshed every three days. The cells were passaged when they reached a 
confluence of 80-90%. The culture medium was removed first. The cell layer was briefly 
rinsed with phosphate buffered saline (PBS) to remove all traces of the serum, which 
contained trypsin inhibitor. 3 ml of 0.25% (w/v) trypsin solution were added to the flask and 
cells were observed under an inverted microscope until the cell layer was dispersed (usually 
within 5 to 15 min). The suspension was transferred to a sterile 50-ml tube and centrifuged at 
1200 rpm for 5 min. After the removal of the supernatant, the cells were resuspended and 
dispensed into new 75-cm2 flasks and incubated at 37 °C.
2.5.2 Primary cell cultures 
Tissues K53, K57 and K63 were obtained, respectively, from three patients with HNSCC who 
underwent surgery in the Department of Oral and Maxillofacial Surgery, Kiel University 
between 2011 and 2013. All patients were treated with surgery with curative intent and had 
negative resection margins. The study was approved by the Institutional Review Board. After 
surgical resection, tissues were cut into several pieces. Remaining tissue was put into a liquid 
nitrogen container for long-term storage. Three small pieces were each promptly transferred to 
a sterile dish with penicillin/streptomycin and hydrocortisone-containing medium, cut into 
small pieces and transferred to a T75 flask with 10 ml of medium. The tissue was incubated in 
a humidified incubator with 5% CO2 at 37 °C. The medium was changed after 7 days and then 
every 3 days.  Tissue fragment and non-adherent blood cells were discarded. When cells 
reached 80% confluence, through time-controlled passage, the primary cell cultures TU53, 
TU57 and TU63 were purified.  
   
Table 1: Information about the primary cell cultures 
Patient 
ID 
Primary cell 
culture 
Gender Age 
(years) 
Histological 
grading 
TNM 
stage 
Tumor 
Site 
1 TU53 female 54 Moderately 
differentiated 
T2N0M0 tongue 
2 TU57 female 42 Moderately 
differentiated 
T2N2M0 tongue 
3 TU63 male 52 Poorly 
differentiated 
T3N0M0 buccal 
2.5.3 Freezing and long-term storage of cells 
SCCs were harvested at 80% confluence for freezing. To collect cells, 5 ml of 0.25% trypsin 
were added to detach the cells. After centrifugation, the pellet was resuspended in warm 
cryopreservation medium containing 90% fetal bovine serum and 10% dimethyl sulfoxide 
(DMSO) in a final amount of 1 ml/vial. The vials were maintained in an alcohol freezing 
container and transferred to a -80 °C refrigerator in which the vials were cooled slowly, by 
about 1 °C every minute, until they reached -80 °C. The cells were stored at -80 °C overnight 
before being transferred to a liquid nitrogen container for long-term storage. Vials of cells 
were stored in the vapor phase of the liquid nitrogen tank. For cell resuscitation, the cells from 
a frozen vial were rapidly thawed to 37 °C, and immediately centrifuged at 1200 rpm for 5 
min. The supernatant was discarded and the pellet suspended in a T75 flask with 10 ml 
DMEM medium containing 10% fetal bovine serum.
 
  
2.6 HNSCC characterization 
2.6.1 Immunocytochemical staining 
After passage, HNSCCs were counted using a hemocytometer, adjusted to a concentration of 
5 x 103/ml and seeded in 6-well chamber slides with 0.5 ml of medium in each well. The cells 
were cultured for 4-5 days until they reached 80-90% confluence. Then medium was 
discarded and the cells were washed twice with warm PBS. The chambers were removed from 
the slides using separator keys. The slides were dried in air at room temperature (RT) for 1 h, 
placed in acetone for 10 min, dried in air for 0.5 h, and then stored at -20 °C.
2.6.1.1 CD90 
Slides were put in methanol for 10 min and then distilled water. Endogenous peroxidase 
activity was blocked with endogenous peroxidase blocking buffer (20 µl per well) for 10 min 
at RT. The slides were then washed in PBS. Endogenous avidin/biotin activity was blocked 
with endogenous avidin/biotin blocking buffer according to the instructions accompanying the 
kit. Each well was incubated at 4 °C overnight with 20 µl of CD90 antibody diluted 1:100 in 
1% bovine serum albumin (BSA) in PBS. Slides were washed three times with PBS for 5 min 
each during incubation. Each well was incubated with 20 ml biotinylated secondary antibody 
for 30 min at RT. Slides were washed three times in PBS with 5 min each during incubation. 
20 µl streptavidin-HRP were applied to each well on slides and incubated for 30 min at RT. 
Slides were washed three times for 5 min in PBS. Working DAB substrate solution was 
mixed and incubated on the slides for a maximum of 5 min at RT. The development of the 
color reaction was stopped by washing with PBS. Slides were counterstained with 
hematoxylin for 1 min and rinsed in flowing water for 10 min. The slides were mounted with 
mounting medium. Sections without primary antibodies served as negative controls. The 
sections were examined and scored using a microscope at 400X magnification.
 
2.6.1.2 Cytokeratin 
The procedure was the same as that described for CD90 except for the incubation conditions 
of the primary and secondary antibodies. Each well was incubated at RT for 1 h with 20 µl of 
cytokeratin antibody diluted 1:500 in 1% BSA in PBS. Slides were washed three times with 
PBS for 5 min each during incubation. Each well was incubated with 20 µl of the biotinylated 
secondary antibody for 15 min at RT.  
Sections without primary antibodies served as negative controls. The sections were examined 
and scored at 400X magnification. 
2.6.1.3 Vimentin 
The procedure was the same as that described for CD90 except for the incubation conditions 
of the primary and secondary antibodies. Each well was incubated at RT for 2 h with 20 µl of 
vimentin antibody diluted 1:200 in 1% BSA in PBS. Slides were washed three times with 
PBS for 5 min each during incubation. Each well was incubated with 20 µl of the biotinylated 
secondary antibody for 15 min at RT.  
Sections without primary antibodies served as negative controls. The sections were examined 
and scored at 400X magnification. 
2.6.1.4 SHH 
The procedure was the same as that described for CD90 except for the incubation conditions 
of the primary and secondary antibodies. Each well was incubated at RT for 2 h with 20 µl of 
SHH antibody diluted 1:100 in 1% BSA in PBS. Slides were washed three times with PBS for 
5 min each during incubation. Each well was incubated with 20 µl of the biotinylated 
secondary antibody for 15 min at RT. 
Sections without primary antibodies served as negative controls. The sections were examined 
and scored at 400X magnification.
 
 
  
2.6.2 Short tandem repeats (STR) 
2.6.2.1 Cell harvesting 
Cells (SCC4, SCC9, SCC15, SCC25, TU53, TU57 and TU63) were released with trypsin. 
After centrifugation at 1200 rpm for 5 min, the liquid was removed completely. Up to 2×105 
cells were suspended and aliquoted into 1.5-ml tubes, flash frozen in liquid nitrogen, then 
stored at -70 °C.
2.6.2.2 Lysis of cells and tissues 
Cell pellets (SCC4, SCC9, SCC15, SCC25, TU53, TU57 and TU63) were suspended 
thoroughly in 200 ml of resuspension solution. 20 ml of proteinase K solution were added to 
the sample, followed by 200 ml of lysis solution C. Cells were vortexed thoroughly and 
incubated at 70 °C for 10 min.
180 ml of lysis solution T were added to tissues K53, K57 and K63, and primary cell cultures 
TU53, TU57 and TU63 respectively, followed by 20 ml of proteinase K solution. The samples 
were mixed by vortex then incubated at 55 °C for 2 h. 200 ml of lysis solution C were added 
to the samples. Then the samples were vortexed and incubated at 70 °C for 10 min. 
2.6.2.3 DNA extraction 
500 ml of column preparation solution were added to each pre-assembled GenElute Miniprep 
Binding Column and centrifuged at 12.000 × g for 1 min. Flow through liquid was discarded. 
200 ml of ethanol (95–100%) were added to the lysate and mixed thoroughly by vortex for 5-
10 s. The entire contents of the tube were transferred to the treated binding column and 
centrifuged at 6500 × g for 1 min. The binding columns were placed in a new 2-mL collection 
tube. 500 mL of wash solution were added to the binding column and centrifuged for 1 min at 
6.500 × g. The binding columns were placed in a new 2-ml collection tube. Another 500 ml of 
wash solution were added to the binding column and centrifuged for 3 min at maximum speed 
(12.000 × g) to dry the binding column. Finally, the binding columns were placed in new 2-ml 
collection tubes. 200 mL of the elution solution were pipetted directly into the center of the 
binding column, incubated for 5 min at RT, and centrifuged for 1 min at 6.500 × g to elute the 
DNA.
2.6.2.4 DNA measurement 
The DNA samples were diluted in TE Buffer and absorbance was measured at 260 nm and 
280 nm by spectrophotometric analysis. An absorbance of 1.0 at 260 nm corresponds to about 
50 mg/ml of double stranded DNA. All DNA samples were prepared to a concentration of 5 
ng/µl.
2.6.2.5 PCR amplification of short tandem repeat (STR) regions 
An AmpFlSTR® Identifiler® Plus PCR Amplification Kit was used. The volume of reaction 
mix was calculated. Preparation details are shown in Table 2. 
Table 2: Preparation of samples for PCR amplification of STR regions 
DNA sample To prepare...
AmpFlSTR® Identifiler® 
Plus Master Mix
10.0 µl
AmpFlSTR® Identifiler® 
Plus Primer Set
5.0 µl
Negative control Add 10 µl of  MiniQ water
Positive control Add 10 µl of 9947A control DNA with the 
concentration of 0.1 ng/µl.
Test sample Add 9.5 µl MiniQ water and 0.5 µl DNA samples 
with concentration of 5 ng/µl to the reaction mix.
The tubes were loaded into a thermal cycler and PCR amplification was performed under the 
thermal cycling conditions shown in Table 3.
 
 
 
 
 
Table 3: Thermal cycling conditions for PCR amplification 
Step1 95 °C 11 min
Step2 94 °C 20 s
Step3 59 °C 3 min
Step4 Go to step 2 28 x
Step5 60 °C 10 min 
Step6 4 °C indefinitely
The whole PCR run lasted 2 h and 30 min. 
2.6.2.6 Detection of STR amplicons 
Samples for electrophoresis were prepared on the 3130 instrument immediately before 
loading. The volumes of Hi-Di™ Formamide and GeneScan™ 500 LIZ® Size Standard were 
calculated for preparation of the samples as shown in Table 4. 
Table 4: STR amplicon detection components 
Reagent Volume per reaction (µl)
GeneScan 500 LIZ Size Standard 0.3
Hi-Di Formamide 11.7
PCR product (including the positive, 
negative samples and allelic ladder)
0.5 µl
The reaction plate was sealed with appropriate septa, and then briefly centrifuged to ensure 
that the contents of each well were collected at the bottom. The DNA within the reaction plate 
was denatured using a thermal cycler for 3 min at 95 °C. The plate was then immediately 
placed on ice for 3 min.
The 3130 Genetic Analyzer was managed following the manufacturer’s instructions. Each 
electrophoresis run was started under the conditions shown in Table 5.
Table 5: Conditions for each electrophoresis run of the 3130 Genetic Analyzer.
Index Amount 
Injection voltage 3000 V
Injection time 10 s
Voltage number steps 40 
Data delay time 1 s
Run time 1200 s
2.6.2.7 Data analysis and STR genotyping 
After electrophoresis, the Data Collection Software stored information for each sample and 
allelic ladder samples in an individual run, which was considered to be the valid standard 
controls while using GeneMapper® ID software for analyses and interpretation of the data.  
2.7 Drug Study 
2.7.1 Preparation of working solutions 
Cilengitide and vismodegib were purchased from Selleck Chemicals (USA). DMSO was 
added to the inhibitor powder to prepare stock solution according to instructions. The dilution 
was calculated and then the stock solution was slowly added to the cell culture medium until 
the desired concentration, from 6.25 µM to 100 µM, was obtained. The solution was then 
mixed by vortex and stored at 4 °C.
2.7.2 MTT test 
A proliferation assay was conducted using an MTT Cell Proliferation Kit (Roche Applied 
Science, IA, USA). Cell lines (SCC4, SCC9, SCC15 and SCC25) and primary cell cultures 
(TU53, TU57 and TU63) were cultured with different concentrations of cilengitide from 6.25 
µM to 100 µM by fold. The negative control groups were cells cultured in medium with 
DMSO, but without either drug. The blank control groups were medium with DMSO, but 
without either of the drugs or cells. Six parallel wells were provided. After a 72-h incubation 
period, 10 µl of MTT labeling reagent was added to every well. Each microplate was 
incubated at 37 °C in a humidified atmosphere for 4 h, then 100 µl solubilization solution was 
added to every well, and the microplate was incubated overnight. Absorbance at 550 nm was 
measured using an automatic microplate reader. 
  
 
2.7.3 BrdU test 
Proliferation with cilengitide or vismodegib was measured using a BrdU Cell Proliferation Kit 
(Roche Applied Science, IA, USA). Cells were re-suspended with DMEM medium containing 
10% fetal bovine serum and seeded onto 96-well plates at a density of 3 × 103 cells/well. The 
final volume of each well was 100 µl. After being cultured at 37 °C for 24 h, 100 µl of 
cilengitide or vismodegib working solution were added at a final concentration of 100, 50, 25, 
12.5 or 6.25 µM. The negative control groups comprised cells with 100 µl medium without 
either drug, and the blank control comprised only medium. Six parallel wells were provided 
for each treatment 72 h after exposure.
10 µl BrdU labeling solution was added to each well and the plates were kept overnight in a 
humidified atmosphere with 5% CO2 at 37 oC. After removing the labeling solution, 200 
µl/well FixDenat solution was added and incubated for 30 min at RT, followed by thorough 
removal of the solution. 100 µl/well of anti-BrdU-POD working solution was then added. 
After incubation for 2 h at RT, the antibody conjugate was removed by rinsing the plate three 
times with washing buffer made in PBS. Subsequently, 100 µl/well substrate solution was 
added and incubated at RT for 15 min until color development was sufficient for photometric 
detection. Prior to the measurement of all samples, 50 µl 1 M H2SO4 were added to the cells 
to stop the reaction. Cells cultured in serum-free culture medium served as controls. Finally, 
absorbance was measured at 450 nm using the microplate reader. The absorbance values of 
each well were saved and analyzed.
2.7.4 Quantitative Real-Time PCR 
2.7.4.1 Drug treatment 
Quantitative real-time PCR was performed to evaluate changes in gene expression of ITGAV, 
ITGBV3, and ITGBV5 after treatment with cilengitide, and of SHH, PTCH1, SMO, SUFU 
and GLI1 after incubation with vismodegib.
Cell lines SCC4, SCC9, SCC15, SCC25 and primary cell cultures TU53, TU57, TU63 were 
re-suspended with DMEM medium containing 10% fetal bovine serum and seeded onto 6-
well plates at a density of 3x104 cells/ml. The final volume of each well was 3 ml. After being 
cultured in an incubator for 24 h, the medium was changed to the working solution with 
cilengitide as the experimental group at a final concentration of 50 µM or 100 µM. For the 
control group, the medium was changed to the working solution without the drug, but with 
DMSO as the solvent. Three parallel wells were provided for each group. The cells were 
harvested 72 h after treatment. 
2.7.4.2 RNA extraction 
An RNeasy Mini Kit was used to extract total RNA. The medium was aspirated, and the cells 
were washed once with PBS. The cells were trypsinized from the well, and centrifuged at 300 
g for 5 min. The supernatant was completely aspirated, and 350 µl of RLT Plus buffer were 
added and mixed by vortex for 1 min. The lysates were pipetted directly into a QIA shredder 
spin column placed in a 2-ml collection tube, and centrifuged for 2 min at maximum speed. 
The homogenized lysate was transferred to a DNA Eliminator spin column placed in a 2 ml 
collection tube and centrifuged for 30 s at 8000 g, and the flow-through was saved. 350 µl of 
70% ethanol were added and mixed. 700 µl of the sample were transferred to an RNeasy spin 
column in a 2-ml collection tube. Samples were centrifuged for 15 s at 8000 g and the flow-
through was discarded. 700 µl of RW1 buffer were added and centrifuged for 15 s at 8000 g 
to wash the spin column membrane. The flow-through was discarded. 500 µl of RPE buffer 
were added and centrifuged for 15 s at 8000 g (≥10,000 rpm) to wash the spin column 
membrane. The flow-through was discarded and the membrane washed again. The RNeasy 
spin columns were placed in a new 1.5-ml collection tube. 30 µl RNase-free water were added 
and centrifuged for 1 min at 8000 g to elute the RNA.
The RNA was diluted in 10 mM Tris·HCl, pH 7.0 and absorbance was measured at 260 nm 
and 280 nm by spectrophotometric analysis. An absorbance of 1.0 at 260 nm corresponds to 
about 44 µg/ml of RNA.
2.7.4.3 Reverse Transcription 
According to the results of RNA measurement, the amount of 1 µg of template RNA was 
calculated for each sample. Genomic DNA elimination reaction was prepared on ice 
according to Table 6. 
Table 6: Genomic DNA elimination reaction components
Component Volume
gDNA wipeout buffer, 7x 2 µl
Template RNA Equivalent to 1µg
RNase-free water Variable
Total amount 14 µl
Samples were incubated for 2 min at 42 °C then placed immediately on ice. The reverse-
transcription master mix (Table 7) was prepared on ice. 
Table 7: Reverse-transcription reaction components
Component Volume
Quantiscript reverse transcriptase 1 µl
Quantiscript RT Buffer, 5x 4 µl
RT Primer Mix 1 µl
Entire genomic DNA elimination reaction 14 µl
Total volume 20 µl
Samples were incubated at 42 °C for 15 min, and then incubated for 3 min at 95 °C to 
inactivate Quantiscript reverse transcriptase. Reverse-transcription reaction components were 
stored at -20 °C.
2.7.4.4 Quantitative Real-Time PCR 
A reaction mix was prepared in accordance with the QuantiTect-SYBR-Green-PCR-
Handbook (Table 8). Capillary cyclers were used for two-step RT-PCR. 
 
Table 8: Quantitative Real-Time PCR reaction mix components
 Component Volume
2x QuantiTect SYBR Green PCR
Master Mix
10 µl
10x QuantiTect Primer Assay 2 µl
Template cDNA 1 µl
RNase-free water 7 µl
Total volume 20 µl
 
The reaction solution was mixed thoroughly, and appropriate volumes were dispensed into 
PCR capillaries. Template cDNA was added to the individual PCR capillaries containing the 
reaction mix. Negative controls contained reaction mix without template cDNA. PCR 
capillaries were placed in the real-time Light Cycler, which was programmed as shown in 
Table 9.  
Table 9: Cycling conditions for two-step qPCR using capillary cyclers
Step Time Temperature
PCR initial
activation step
15 min 95 G
Denaturation 15 s 94 G
Annealing 20 s 55 G
Extension 20 s 72 G
Number of cycles 40  
All primers (Table 10) were obtained from QIAGEN. The results were analyzed using the 
Light Cycler Software, version 3. The final PCR products were evaluated by agarose gel 
electrophoresis to verify the size of the cDNA products by comparison with a low range DNA 
ladder of 25-500 bp. Thus, 10-µl aliquots of each sample were electrophoresed on a 2.0% 
agarose gel in TBE buffer stained with ethidium bromide and photographed using the 
BioDocAnalyze System. 
Table 10: List of all primers for RT-PCR
Gene (official 
name) 
Gene 
(abbrevia
ted) 
Primer 
Size 
Forward primer Reverse primer 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
GAPDH 95 bp 
ACAACTTTGGT
ATCGTGGAAGG 
GCCATCACGCC
ACAGTTTC 
Integrin, alpha V ITGAV 125 bp 
GCTGTCGGAGA
TTTCAATGGT 
TCTGCTCGCCA
GTAAAATTGT 
Integrin, beta 3 ITGB3 116 bp 
GTGACCTGAAG
GAGAATCTGC 
CCGGAGTGCAA
TCCTCTGG 
Integrin, beta 5 ITGB5 61 bp 
AACTCGCGGAG
GAGATGAG 
AACTCGCGGAG
GAGATGAG 
Sonic hedgehog SHH 136 bp 
CTCGCTGCTG
GTATGCTCG 
ATCGCTCGGA
GTTTCTGGAG
A 
Patched 1 PTCH1 119 bp 
ACTTCAAGGG
GTACGAGTAT
GT 
TGCGACACTC
TGATGAACCA
C 
Smoothened, 
frizzled class 
receptor 
SMO 89 bp 
GTGAGCGCCT
CATCGAAGT 
AGCGACTGGA
CGTAGGTGA 
Suppressor of 
fused homolog 
SUFU 92 bp 
AGACCCCTTG
GACTATGTTA
GC 
CGAAGCTGAT
GTAGTGCCAG
T 
GLI family zinc 
finger 1 
GLI1 148 bp 
AGCGTGAGCC
TGAATCTGTG 
CAGCATGTAC
TGGGCTTTGA
A 
 
 
2.8 Statistical analysis 
All experiments were performed in triplicate. The absorbance values of the MTT and BrdU 
tests are presented as means ± SD. Data were analyzed by one-way analysis of variance for 
comparison with controls. If significant F-statistics from analysis of variance existed, this test 
was followed by a Dunnett post-hoc multiple comparison among all groups. A P-value of 
<0.05 was considered statistically significant.  
3. Results 
3.1 SCC morphology 
Cells began to adhere to the disk after 2 to 3 h. They exhibited first as small, round, non-
uniform sized dots, gradually extending into short or long spindles and finally forming 
polygons and an epithelium-like morphology within 24 h. All cells showed a homogeneous 
epithelium-like shape (Fig. 4). These cells reached 80-90% confluence every 4 to 5 days. 
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Figure 4: Morphology of SCCs under the microscope at a magnification of 400X. Adherent 
cells were polygonal epithelial-like and cobblestone-like. Some round cells with multiple 
nuclei are visible, in which the nucleoli are clear and unequal in size; there were up to five or 
six nucleoli present.
3.2	Immunocytochemical	staining	
To identify the biological characteristics of the primary cell cultures and cell lines, four kinds 
of standard immunocytochemical staining were performed. 
 CD
CD90 is a cell surface protein with a single V-like immunoglobulin domain. CD90 was 
originally discovered as a thymocyte antigen, and used as a marker for a variety of stem cells, 
axonal processes of mature neurons, and a fraction of fibroblasts and myofibroblasts. All cells 
expressed negative CD90 (Figure. 5).  
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Figure 5: Immunocytochemical staining of CD90 in HNSCC cells. Each well was incubated 
at 4 °C overnight with 20 µl of CD90 antibody diluted 1:100 in 1% BSA in PBS, and with 20 
ml biotinylated secondary antibody for 30 min at RT. Sections without primary antibodies 
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that served as negative controls are also shown. The sections were examined and scored using 
a microscope at 400X magnification. Expression of CD90 in cell lines (A, C, E, G) and 
primary cell cultures (I, K, M) was negative.
3.2.1 Cytokeratin staining 
Cytokeratin is characteristic of epithelial cells. Anti-cytokeratin is a broadly reactive reagent, 
which recognizes epitopes present in most human epithelial tissues. Both cell lines and 
primary cell cultures showed strong expression of cytokeratin (Fig. 6). 
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Figure 6: Immunocytochemical staining of cytokeratin in HNSCC cells. Each well was 
incubated at RT for 1 h with 20 µl of cytokeratin antibody diluted 1:500 in 1% BSA in PBS, 
and with 20 µl of the biotinylated secondary antibody for 15 min at RT. Sections without 
primary antibodies that served as negative controls are also shown. The sections were 
examined and scored using a microscope at 400X magnification. Cell lines (A, C, E, G) 
expressed strong positive cytokeratin. Primary cell cultures (I, K, M) showed modest 
expression of cytokeratin.
3.2.2. Vimentin staining 
Vimentin is the major cytoskeletal component of mesenchymal cells. It is often used as a 
marker of mesenchymally derived cells and has been used as a sarcoma tumor marker to 
identify mesenchyme. All cells showed moderate expression of vimentin (Fig. 7). 
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Figure 7: Immunocytochemical staining of vimentin in HNSCC cells. Each well was 
incubated at RT for 2 h with 20 µl of vimentin antibody diluted 1:200 in 1% BSA in PBS, and 
with 20 µl of the biotinylated secondary antibody for 15 min at RT. Sections without primary 
antibodies that served as negative controls are also shown. The sections were examined and 
scored using a microscope at 400X magnification. Cell lines (A, C, E, G) and primary cell 
cultures (I, K, M) showed modest expression of vimentin.
3.2.3 SHH staining 
Sonic hedgehog (SHH) is a protein that controls cell division of adult stem cells and has been 
implicated in the development of some cancers, such as HNSCC, small cell lung cancer, 
pancreatic carcinoma, prostate cancer and gastric cancer. All cells expressed SHH (Fig. 8).
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Figure 8: Immunocytochemical staining of SHH in HNSCC cells. Each well was incubated at 
RT for 2 h with 20 µl of SHH antibody 1:100 diluted in 1% BSA in PBS, and with 20 µl of 
the biotinylated secondary antibody for 15 min at RT. Sections without primary antibodies 
that served as negative controls are also shown. The sections were examined and scored using 
a microscope at 400X magnification. Cell lines (A, C, E, G) and primary cell cultures (I, K, 
M) showed modest expression of SHH.
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3.3 STR 
Sixteen core STR loci (Table 11) had been identified for estimating the homology of individual tissue and primary cell culture genetic profiles. 
The DNA profiling showed that K53 and TU53, K57 and TU57, K63 and TU 63 are all homologous. 
Table 11: Sixteen core STR loci of individual tissue and primary cell culture samples 
  D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 
K53 13; 15 28.2; 33 11; 11 OL; OL 17; 17 9.3; 9.3 8; 13 11; 11 
TU53 OL; 15 28,2; 33 11; 11 OL; OL 17; 17 9,3; 9,3 8; 13 11; 11 
K57 10; 15 29.2; 32 OL; 12 OL; 10.2 16; 16 7; 9.3 8; 11 10; 11 
TU57 10; 15 29.2; 32 10; 12 OL; OL 16; 16 7; 9.3 8; 11 10; 11 
K63 13; 15 32; 32 9; 12 OL; 10.2 15; 18 7; 7 10; 14 10; 12 
TU63 13; 15 32; 32 OL; 12 OL; 10.2 15; 18 7; 7 10; 14 10; 12 
         
 D2S1338 D19S433 vWA TOPX D18S51 A…. D5S818 FGA 
K53 17; 17 13; 14.2 16; 16 OL; OL 14; 18.2 X; X OL; OL 22; 26 
TU53 17; 17 13; 14,2 16; 16 OL; OL 18,2; 18,2 X, X OL; OL OL; OL 
K57 OL; OL 13; 14.2 15; 18 OL; OL 13; 21.2; 22.2 X; X OL; OL OL; 25 
TU57 17; 17 13; 14.2 15; 18 8; 9 OL; 21.2; 22.2 X; X OL; OL 21; 21; 25 
K63 24; 25 12; 12.2 19; 19 OL; OL 12; 16.2 X; Y OL; OL 23; 23 
TU63 24; 25 12; 12.2 19; 19 OL; OL 12; 16.2 X; Y OL; OL 23; 23 
 
3.4	Drug	tests	
3.4.1 MTT test  
Proliferation of cell lines and primary cell cultures was suppressed by cilengitide or 
vismodegib in a dose dependent manner. Primary cell cultures showed more 
significant suppression than HNSCC cell lines. In primary cell cultures, the same 
concentration of drug could have a stronger inhibition effect (Fig. 9).
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Figure 9: Cilengitide or vismodegib suppressed HNSCC cell proliferation. Cells were 
plated at a density of 1 × 105 cells per well in a 96-well plate and were allowed to 
attach before incubation in medium containing cilengitide (A and B) or vismodegib 
(C and D) for 72 h. Absorbance at 550 nm was assessed with MTT tests. Mean ± 
SEM (n=8). * P<0.05, ** P<0.01 (compared to the control). Proliferation of cell lines 
and primary cell cultures was suppressed by cilengitide (A and B) or vismodegib (C 
and D) in a dose dependent manner. 
3.4.2 BrdU test  
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Proliferation of cell lines and primary cell cultures was suppressed by cilengitide or 
vismodegib. Primary cell cultures expressed more significant suppression of growth 
than HNSCC cell lines, especially with cilengitide (Fig. 10). 
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Figure 10: Cilengitide or vismodegib suppressed HNSCC cell proliferation. Cells 
were plated at a density of 1 × 105 cells per well in a 96-well plate and were allowed 
to attach before incubation in medium containing cilengitide (A and B) or vismodegib 
(C and D) for 72 h. Absorbance at 450 nm was assessed using a BrdU test. Mean ± 
SEM (n=8). * P<0.05, ** P<0.01 (compared to the control). Proliferation of cell lines 
and primary cell cultures was suppressed by cilengitide (A and B) or vismodegib (C 
and D) in a dose dependent manner. 
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3.4.3 Real time PCR 
3.4.3.1 Cilengitide 
Results showed that 50 µM cilengitide led to significantly reduced expression of the 
integrin target genes ITGAV, ITGB3, and ITGB5 (Fig. 11: A1, A2 and A3) compared 
with the control. But incubation with 100 µM cilengitide led to significantly increased 
expression of those genes both in cell lines and primary cell cultures (Fig. 11: B1, B2 
and B3).
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Figure 11: Effect of cilengitide on the expression of integrin target genes. GAPDH-
normalized mRNA levels of ITGAV, ITGB3, ITGB5 revealed by real-time PCR in 
cell lines and primary cell cultures after 72 h of treatment with cilengitide at a 
concentration of 50 µM (A1, B1, C1) or 100 µM (A2, B2, C2). Gene expression was 
normalized to that of endogenous GAPDH in each cell line. Data represent the mean ± 
SD of three independent experiments. (Two-tailed t test, *: P<0.05; **: P<0.01)  
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3.4.3.2 Vismodegib 
Results showed that 50 µM or 100 µM vismodegib led to significantly reduced GLI1 
gene expression (Fig. 12: B1, and B2), as target gene expression was less than that of 
the control. However, incubation with 100 µM vismodegib led to increased expression 
of SHH, PTCH1, SMO, and SUFU both in cell lines and primary cell cultures (Fig. 
12: A2, C2, D2 and E2).  
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Figure 12: Effect of vismodegib on the expression of integrin target genes. A1, B1, 
C1, D1, E1, F1: GAPDH-normalized mRNA levels of SHH, PTCH1, SMO, SUFU 
and GLI1 revealed by real-time PCR in cells treated with DMSO or 50 µM 
vismodegib for 72 h. A2, B2, C2, D2, E2, F2: GAPDH-normalized mRNA levels of 
SHH, PTCH1, SMO, SUFU and GLI1 revealed by real-time PCR in cells treated with 
DMSO or 100 µM vismodegib for 72 h. Gene expression was normalized to that of 
endogenous GAPDH in each cell line. Data represent the mean ± SD of three 
independent experiments. (Two-tailed t test, *: P<0.05; **: P<0.01) 
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4. Discussion 
4.1 Cilengitide 
Tumor invasion and metastasis are the main causes of death in cancer patients and are 
also the key reasons for difficulties in developing radical cures. The tumor metastasis 
process involves interactions among a variety of cell adhesion molecules, ECM and 
other blood cells (Liotta and Stetler-Stevenson, 1991). Integrins are important 
adhesion molecules and play a regulatory role in many critical biological processes 
such as cell proliferation, invasion, apoptosis, metastasis, and angiogenesis (Varner 
and Cheresh, 1996, Lester and McCarthy, 1992). 
As RGD peptides are non-immunogenic, nontoxic and have no adverse effects, they 
have emerged as an area of intensive research in the field of inhibition of tumor 
metastasis through their interaction with integrins. Exogenous RGD peptides can be 
used as competitive integrin inhibitors to block the downstream signaling pathways of 
integrins through specific binding to integrins, thereby producing significant 
inhibition of tumor cell proliferation, adhesion, metastasis and angiogenesis 
(Jovanovic et al., 2007). Therefore, small peptides containing the RGD sequence have 
important clinical value in cancer diagnosis and treatment, and have attracted 
considerable research interest. Researchers have designed and synthesized a series of 
tripeptide RGD-containing peptides or peptide analogues that inhibit the association 
of ECM ligand proteins with integrins, for the treatment of malignant tumors 
(Kumagai et al., 1991). Cilengitide is a synthetic, cyclic peptide containing the RGD 
sequence (cRGDf (n-Me) V) and is internationally recognized as a small molecule 
antagonist of integrin αvβ3 and αvβ5 (Ten Hagen et al., 2013). In our present study, 
we exposed SCC to cilengitide in vitro and studied the effects of cilengitide exposure 
at different concentrations on cell proliferation. Our results showed that cilengitide 
could significantly inhibit the proliferation of SCCs in a dose-dependent manner. For 
a given concentration, cilengitide exerted a stronger suppression effect on the 
proliferation of primary cell cultures than on cell lines, suggesting that primary cell 
cultures may retain more of their internal biological characteristics (Manikandan et 
al., 2016). Thus, the application of drugs to the cell lines or primary cell cultures 
resulted in different effects. 
 
While cilengitide has entered phase I and phase II clinical trials for some malignant 
tumors, such as malignant glioma (Nabors et al., 2007, MacDonald et al., 2008, Albert 
et al., 2006), research about its application to head and neck cancer, especially oral 
squamous carcinoma, is just beginning, and no data are currently available. Although 
a small proportion of patients with glioma respond to cilengitide when it is 
administered at high doses (Nabors et al., 2007), there is currently little evidence that 
it is effective in the treatment of other human cancers (Hariharan et al., 2007, Gerstner 
et al., 2015, Vansteenkiste et al., 2015). No study has addressed whether cilengitide-
conferred inhibition of the expression of integrin can suppress proliferation and 
induce apoptosis of oral squamous carcinoma cells.  
It remains unknown whether RGD peptides, as competitive integrin inhibitors, can 
directly inhibit integrin gene expression. In this study, we used RT-PCR to detect 
mRNA expression of ITGAV, ITGB3 and ITGB5 before and after exposure to 
cilengitide. Our results showed that 50 µM cilengitide led to significantly reduced 
expression of ITGAV, ITGB3 and ITGB5. But, interestingly, with 100 µM 
cilengitide, expression of ITGAV, ITGB3 and ITGB5 increased significantly both in 
cell lines and primary cell cultures. One possible explanation for this result is that 
intergrin overexpression is associated with chemotherapy resistance that could prevent 
patients from achieving complete remission. RGD peptides are competitive inhibitors 
which impede the binding of integrins to their ECM ligands through their association 
with integrins, thereby blocking biological events downstream of the integrin-
mediated pathways and inhibiting tumor invasion and metastasis. The mechanism by 
which integrin expression is inhibited following exposure to RGD peptides remains 
undefined. A possible explanation may be that the binding between RGD peptides and 
integrin induces changes in the conformation and molecular weight of integrin, 
resulting in undetectable integrin expression. In addition, there may exist negative and 
positive feedback mechanisms acting on the expression level of integrins on the cell 
surface and their ECM ligands. Exogenous RGD peptides might bind to integrins in 
large quantities, leaving a large number of integrin ligands in the ECM unoccupied, 
thereby creating negative feedback inhibition on the secretion of integrins, hence 
reducing integrin expression. Or exogenous RGD peptides might bind to integrins in 
huge quantities covering all integrins, thereby leaving free a huge number of integrin 
ligands in the ECM, creating positive feedback on the secretion of integrins and hence 
increasing integrin expression. Currently, no conclusive experimental evidence is 
available to support these possibilities and further research is needed. 
Reynolds et al (2009) found evidence in vivo that low (nanomolar) concentrations of 
cilengitide can paradoxically stimulate tumor growth and angiogenesis by altering 
αvβ3 integrin and vascular endothelial growth factor receptor-2 trafficking, thereby 
promoting endothelial cell migration to VEGF. Research had already shown that 
αvβ5, but not αvβ3, is overexpressed in HNSCC tissue, whereas both integrins are 
expressed on sprouting vessels (Fabricius et al., 2011). Preclinical studies in mice 
bearing xenografts (A431 epidermoid carcinoma or U87MG glioblastoma cells) 
demonstrated a synergistic effect between cetuximab (10 mg/kg intra-peritoneal 
weekly) and cilengitide (25 mg/kg intra-peritoneal 5×/week). The phase I part of the 
advantage study demonstrated cilengitide plus cisplatin, 5-FU, and cetuximab (PFE) 
was well tolerated by patients with recurrent and/or metastatic squamous cell 
carcinoma of the head and neck (Vermorken et al., 2011). The most common 
cilengitide-related adverse events included nausea, anorexia, and asthenia, but no 
dose-limiting or unexpected toxicities were reported. Phase I/II trials showed the 
potential of cilengitide activity as a single-agent therapy in recurrent glioblastoma 
multiforme (Reardon et al., 2008), and as a concomitant and adjuvant therapy with 
standard chemoradiotherapy in newly diagnosed glioblastoma multiforme (Stupp et 
al., 2010, Nabors et al., 2012). Furthermore, in phase II of a randomized phase I/II 
advantage trial, Vermorken et al. (2014) showed that, compared with cetuximab and 
platinum-based chemotherapy alone, the addition of cilengitide with cisplatin, 5-
fluorouracil, and cetuximab was well tolerated, but did not result in a better outcome. 
Therefore, this combination cannot be recommended for further development in 
treating patients with recurrent/metastatic squamous cell carcinoma of the head and 
neck. Controversially, some research showed the results of combination therapy, 
either with irradiation or other drug chemotherapy (Heiduschka et al., 2014, Eisele et 
al., 2014, Vansteenkiste et al., 2015), had better outcomes than monotherapy. 
In summary, RGD peptides can inhibit tumor cell proliferation and hold tremendous 
promise in tumor chemotherapy. However, research on the role of RGD peptides in 
cancer therapy is still in its early stages and the underlying mechanism is still poorly 
understood (Vansteenkiste et al., 2015). The key issue is how to identify more integrin 
ligands with higher affinity, namely peptides containing the RGD sequence. As phage 
library techniques become increasingly sophisticated and novel screening techniques 
continue to be adopted, we believe that RGD-containing small molecule synthetic 
peptides will be seriously considered in tumor chemotherapy in the near future and 
look set to offer broader chemotherapy drug options for HNSCC. 
4.2 Vismodegib 
Overexpressed or mutated proteins in the HH pathway or activation of the related 
transcription factors are apparent in a variety of human malignancies, including 
HNSCC, and are associated with poor prognosis (Cavicchioli Buim et al., 2011, Yan 
et al., 2011, Thomas et al., 2005), so this study is of particular importance (Onishi and 
Katano, 2011). Inappropriate activation of HH signaling by overexpression or 
mutation was found to increase snail protein expression, with a loss of cellular 
adhesion, activate anti-apoptotic genes and angiogenic factors, reduce apoptotic gene 
activation, and interfere in the cell-cycle sequence (Galimberti et al., 2012, Kim et al., 
2014). These HH-mediated properties may contribute to tumor development and 
facilitate tumor growth and spread, with consequent poor prognosis for different 
human malignancies. In healthy adult tissues, the HH pathway regulates stem cells 
during regeneration and tissue repair (Beachy et al., 2004, Mimeault and Batra, 2006), 
but disturbances within this system may easily lead to cancer cell formation. Tumor 
repopulation after chemotherapy might be promoted by HH signaling, with the 
consequences of early recurrence, treatment resistance, and poor prognosis (Chen et 
al., 2007, Liu et al., 2014, Varnat et al., 2009). Jaggupilli and Elkord (2012) reported 
HH pathway overexpression (SMO and GLI1) in putative HNSCC cancer stem cell 
subpopulations (CD24, CD44 and CD133), although there is currently no agreed 
consensus about stem cell markers in HNSCC. Data from studies of HH protein 
expression in HNSCC have been reported, but the samples sizes were small, not all 
components were considered (Schneider et al., 2011), and results concerning 
expression patterns were partly controversial (Wang et al., 2012). A recent study 
demonstrated increased expression of most HH pathway proteins, especially GLI1.  
Vismodegib (GDC-0449) is a synthetic HH inhibitor. The substance acts as a 
cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part 
of the HH signaling pathway. SMO inhibition causes the transcription factors GLI1 
and GLI2 to remain inactive, which prevents the expression of tumor mediating genes 
within the pathway. Phase II trials with vismodegib have been successfully performed 
for skin, brain, and breast tumors (see the listing of current clinical trials of the 
National Cancer Institute, www.cancer.gov), and other tumor entities are currently 
under investigation. In a phase II, randomized, double-blind, placebo-controlled trial, 
vismodegib was tested to provide an estimate of efficacy in the setting of second or 
third complete remission in 104 ovarian cancer patients (Kaye et al., 2012). Although 
numerical improvements were observed, a clinically meaningful improvement in 
progression-free survival for vismodegib versus placebo maintenance could not be 
demonstrated, and HH ligand-expression frequency was lower than expected. One 
possible explanation for this result is that HH ligand overexpression is associated with 
chemotherapy resistance that could prevent patients from achieving complete 
remission. Alternatively, it is conceivable that HH ligand overexpression is actually 
associated with a lower probability of relapse, leading to a lower prevalence of HH-
positive ovarian cancer in the patients of this study (Kaye et al., 2012). This report 
stressed the importance of an appropriate patient selection strategy for further studies. 
In another analysis of a multi-center, randomized, double-blind, placebo-controlled, 
phase II trial in patients with the basal-cell nevus (Gorlin) syndrome, results indicated 
that vismodegib reduces basal-cell carcinoma tumor burden and prevents new basal-
cell carcinoma growth in patients with basal-cell nevus syndrome. Adverse events 
associated with vismodegib frequently led to interruption of treatment, followed by 
basal-cell carcinoma recurrence (Tang et al., 2016). Until now, no clinical trials of 
vismodegib have been carried out on patients with HNSCC. 
As reported in our study, SMO inhibition by vismodegib has demonstrated a potential 
inhibitory effect against tumor growth in tumor cell lines and primary cell cultures. 
The inhibitory effect was more pronounced on primary cell cultures than on cell lines. 
Vismodegib treatment also led to down-regulation of the HH target gene GLI1. But 
our study has demonstrated that 100 µM vismodegib resulted in up-regulation of 
SHH, SMO, PTCH and SUFU. One possible explanation for this result is that HH 
ligand overexpression is associated with chemotherapy resistance that could prevent 
patients from achieving complete remission. Bahra et al. reported on the synergistic 
effects of cyclopamine and gemcitabine in the reduction of tumor volume in 
pancreatic adenocarcinoma xenografts and postulated a new therapeutic approach 
(Bahra et al., 2012). Lapatinib suppresses colony formation of epithelial HNSCC 
cells, and in combination with cisplatin, its efficacy is increased (Schrader et al., 
2012). Liebig et al. (2017) provided ex-vivo evidence for the potential of vismodegib 
in HNSCC therapies, especially if combined with cetuximab, cisplatin and docetaxel. 
Vismodegib suppressed proliferation and colony formation. This means that 
combined treatment with the guideline cytostatic drugs cisplatin or docetaxel 
synergistically contributed to even greater inhibition of colony formation of HNSCC 
than single drug therapy. 
In conclusion, the direct blockade of an activated pathway that is responsible for, or at 
least involved in, tumor growth is a promising goal in cancer therapy. Also, 
combinations of drugs targeting SMO with guideline-conforming cytostatic drugs 
may be superior to single agent therapy. According to our results, assuming 
vismodegib can be introduced into clinical practice, it is quite possible that a 
promising benefit in HNSCC could also be expected. Our results encourage further 
investigation concerning the HH pathway in HNSCC and the development of new 
agents targeting this signaling cascade with less serious adverse effects than 
vismodegib.  
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Due to the low 5-year survival rate and the high recurrence rate of HNSCC, new 
chemotherapeutic strategies are of high clinical interest. Integrins are important 
adhesion molecules and play a regulatory role in many critical biological processes 
such as cell proliferation, invasion, apoptosis, metastasis, and angiogenesis in 
squamous cell carcinoma. Cilengitide is a cyclized RGD containing pentapeptide that 
selectively blocks activation of the integrins. Recently, growing evidence has 
suggested aberrant activation of the HH pathway in squamous cell carcinoma plays a 
critical role during cancer development. Vismodegib (GDC-0449) is an orally 
administered agent that selectively suppresses SMO activity.  
Most previous studies used cell lines purchased from commercial companies. These 
cell lines may already have differentiated and lost some of their potential 
characteristics as tumor cells. Accordingly, we isolated and identified primary 
HNSCC cell cultures, and evaluated the effects of cilengitide and vismodegib on both 
cell lines and primary cell cultures. The application of drugs to the cell lines or 
primary cell cultures produced different results. 
Four tongue squamous cell carcinoma cell lines (SCC4, SCC9, SCC15 and SCC25) 
were obtained from the American Type Culture Collection. Three primary cell 
cultures (TU53, TU57 and TU63) were obtained, respectively, from three patients 
with HNSCC, who underwent surgery. DNA profiling using STRs showed that K53 
and TU53, K57 and TU57, K63 and TU 63 are all homologous. 
To identify the biological characteristics of the primary cell cultures and cell lines, 
four kinds of typical immunocytochemical staining were performed. All cells 
expressed negative CD90, excluding a fibroblast source. Both cell lines and primary 
cell cultures strongly expressed cytokeratin, which is characteristic of epithelial cells. 
All cells showed moderate expression of vimentin, demonstrating a mesenchymally 
derived sarcoma tumor. All cells expressed SHH, indicating activation of the HH 
pathway in HNSCC.  
MTT and BrdU tests showed proliferation of cell lines and primary cell cultures were 
suppressed by cilengitide or vismodegib in a dose dependent manner without 
exception. Primary cell cultures expressed more significantly depressed growth than 
cell lines. 6.25 M of cilengitide had a significant inhibitory effect on primary cell 
cultures, but a concentration as high as 100 M was needed to produce a similar 
effect on cell lines. 50 M vismodegib significantly inhibited the proliferation of 
primary cell cultures, but for cell lines the concentration needed to be as high as 100 
M. Primary cell cultures may retain more of their internal biological characteristics. 
Therefore, individualized treatment may be necessary with regard to the different 
stages of tumor progression. 
RT-PCR results showed that 50 µM cilengitide significantly reduced ITGAV, ITGB3, 
and ITGB5 gene expression. But incubation with 100 µM cilengitide significantly 
increased expression of ITGAV, ITGB3, and ITGB5 in all cells. Cilengitide can 
inhibit tumor cell proliferation and integrin gene expression at low concentrations, 
holding tremendous promise in tumor chemotherapy. However, the research on the 
role of RGD peptides in cancer therapy is still in its early stages and further 
investigations are required.
RT-PCR results also showed that GLI1 gene expression was reduced significantly by 
incubation with 50 µM or 100 µM vismodegib. The results demonstrated that 
vismodegib could effectively block activation of HH signal pathway.
Findings from current study have potentially important clinical implications. We 
found that the integrin inhibitor cilengitide and HH signal inhibitor vismodegib can 
inhibit HNSCC cell proliferation and reduce target gene expression at certain 
concentrations. Patients with HNSCC tumors may benefit from an individualized 
therapeutic strategy. 
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7. Appendix
Table 12: MTT tests on different cells with different concentration of cilengitide (72 h) (Means ± SD)
 
Cilengitide (µM) 0 6.25 12.5 25 50 100 
SCC4 1.014±0.069  1.007±0.081 1.024±0.125  1.059±0.066  0.938±0.073  0.755±0.027  
SCC9 1.009±0.058  1.020±0.061   1.006±0.051  0.937±0.038  0.802±0.038  0.641±0.082  
SCC15 1.004± 0.114 0.876± 0.076 0.901±0.069  0.884± 0.041 0.886±0.066  0.452±0.079  
SCC25 1.003± 0.045 1.018± 0.039 1.017±0.077  1.027± 0.038 1.016±0.094  0.570± 0.070 
TU53 1.003± 0.057 0.969± 0.040 0.961± 0.052 0.967± 0.037 0.879±0.045  0.453±0.032  
TU57 1.003±0.068  0.590± 0.032 0.542±0.046   0.554±0.076  0.535± 0.056 0.433±0.017  
TU63 0.994± 0.054 0.672± 0.071 0.484±0.050  0.409±0.027  0.362± 0.017 0.364± 0.040  
 
Table 13: MTT tests on different cells with different concentration of vismodegib (72 h) (Means ± SD)
 
Vismodegib (µM) 0 6.25 12.5 25 50 100 
SCC4 1.006±0.035  0.985±0.070  0.955±0.071  0.959±0.052  0.894±0.097  0.760±0.021  
SCC9 1.003±0.060  0.954±0.056  0.924±0.093  0.923±0.063  0.860±0.058  0.756±0.059  
SCC15 1.004±0.114  0.928±0.076  0.885±0.101  0.943±0.058  0.908±0.057  0.536±0.044  
SCC25 1.003± 0.045 0.972±0.053  1.022±0.038  0.934±0.038  0.894±0.063  0.365±0.038  
TU53 1.002±0.039  1.001±0.035  0.977±0.035  0.950±0.046  0.884±0.047  0.466±0.055  
TU57 0.998±0.060  0.917±0.032  0.928±0.043  0.883±0.060  0.802±0.022  0.622±0.024  
TU63 0.995±0.062  0.932±0.041  0.906±0.041  0.899±0.056  0.881±0.055  0.775±0.049   
Table 14: BrdU tests on different cells with different concentration of cilengitide (72 h) (Means ± SD)
   
Cilengitide (µM) 0 6.25 12.5 25 50 100 
SCC4 1.000±0.056  1.075±0.027  1.044±0.044  1.045±0.038  1.040±0.053  0.807±0.034  
SCC9 1.000±0.079  1.031±0.041  0.950±0.052  0.967±0.057  0.895±0.076  0.887±0.100  
SCC15 1.000± 0.069 1.030±0.023   1.022±0.044  1.027±0.061  1.008±0.036  0.587±0.100  
SCC25 1.000±0.042  0.922±0.048  1.011±0.043  1.031±0.052  1.078±0.034  0.643±0.082  
TU53 1.000±0.084  0.970±0.048  1.021±0.050  0.969±0.064  1.014±0.043  0.696±0.061  
TU57 1.000±0.091  0.797±0.128  0.690±0.138  0.633±0.094  0.544±0.090  0.336±0.096  
TU63 1.000±0.114  0.887±0.096  0.670±0.075  0.407±0.032 0.374±0.019  0.328±0.013  
 
Table 15:  BrdU tests on different cells with different concentration of vismodegib (72 h) (Means ± SD)
 
Vismodegib (µM) 0 6.25 12.5 25 50 100 
SCC4 1.000±0.032  1.034±0.036  0.949±0.139  0.991±0.041  0.945±0.051  0.789±0.041  
SCC9 1.000±0.073  0.956±0.092  0.918±0.081  0.892±0.083  0.843±0.044  0.765±0.049  
SCC15 1.000±0.035  0.934±0.047  0.913±0.072  0.854±0.058  0.812±0.028  0.533±0.028  
SCC25 1.000±0.073  0.971±0.047  0.960±0.039  0.948±0.048  0.843±0.039  0.487±0.228  
TU53 1.000±0.078  1.010±0.067  0.956±0.070  0.964±0.058  0.907±0.069  0.695±0.066  
TU57 1.000±0.057  0.976±0.058  0.917±0.097  0.884±0.065  0.781±0.059  0.524±0.032  
TU63 1.000±0.114  0.966±0.127  0.958±0.237  1.004±0.084  0.694±0.161  0.611±0.144  
 
 
 
 
Table 16: Relative mRNA expression level of genes of cells with 50 µM cilengitide detected by qPCR (72 h)
 
 SCC4 SCC9 SCC15 SCC25 TU53 TU57 TU63 
ITGAV 1.17±0.06 1.00±0.09 0.87±0.26 0.70±0.03 0.92±0.04 1.08±0.15 0.86±0.32 
ITGB3 1.01±0.19 0.37±0.06 0.82±0.06 0.62±0.05 0.57±0.02 0.97±0.02 0.94±0.12 
ITGB5 0.83±0.13 1.13±0.21 0.72±0.11 0.57±0.18 0.75±0.06 1.23±0.25 1.38±0.17 
 
Table 17: Relative mRNA expression level of genes of cells with 100 µM cilengitide detected by qPCR (72 h)
 
 SCC4 SCC9 SCC15 SCC25 TU53 TU57 TU63 
ITGAV 4.38±0.13 1.05±0.04 1.98±0.38 1.72±0.18 1.48±0.18 1.55±0.25 1.44±0.05 
ITGB3 8.30±1.06 0.79±0.20 3.51±0.27 7.15±0.26 3.04±0.62 0.71±0.14 8.48±0.61 
ITGB5 2.35±0.07 0.74±0.10 1.47±0.22 1.16±0.05 1.23±0.04 1.82±0.12 3.12±0.20 
 
  
Table 18: Relative mRNA expression level of genes of cells with 50 µM vismodegib detected by qPCR (72 h)
 
 SCC4 SCC9 SCC15 SCC25 TU53 TU57 TU63 
SHH 1.13±0.17 0.64±0.12 1.42±0.15 0.47±0.28 1.69±0.15 1.37±0.20 0.69±0.23 
PTCH1 1.07±0.07 1.37±0.21 1.17±0.29 0.73±0.24 1.07±0.19 1.64±0.24 0.76±0.26 
SMO 2.91±0.32 1.16±0.32 2.46±0.29 2.19±0.26 2.28±0.20 1.30±0.16 0.84±0.31 
SUFU 1.39±0.17 1.29±0.10 1.45±0.12 0.87±0.22 1.34±0.03 1.12±0.19 0.76±0.34 
GLI1 1.01±0.15 0.62±0.16 0.96±0.19 0.35±0.15 0.90±0.12 0.85±0.26 0.60±0.37 
 
Table 19: Relative mRNA expression level of genes of cells with 100 µM vismodegib detected by qPCR (72 h)
 
 SCC4 SCC9 SCC15 SCC25 TU53 TU57 TU63 
SHH 1.98±0.16 1.95±0.49 2.29±0.21 4.37±0.71 4.91±0.18 1.27±0.66 0.98±0.08 
PTCH1 1.72±0.24 1.78±0.06 1.20±0.29 1.16±0.13 1.89±0.22 1.11±0.11 2.58±0.13 
SMO 1.56±0.44 3.41±0.76 1.33±0.22 1.25±0.18 4.31±0.7 0.78±0.29 2.93±0.23 
SUFU 1.94±0.26 1.88±0.68 1.41±0.13 2.49±0.23 1.15±0.12 0.94±0.29 2.19±0.13 
GLI1 0.60±0.23 0.68±0.11 0.81±0.23 0.17±0.17 0.96±0.1 0.64±0.05 0.92±0.14 
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